Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel.

被引：0
|
作者：
Tripathi, Abhishek
Xie, Wanling
Sweeney, Christopher
Choudhury, Atish Dipankar
Pomerantz, Mark
Wei, Xiao X.
Taplin, Mary-Ellen
Choueiri, Toni K.
Lee, Gwo-Shu Mary
Kantoff, Philip W.
Harshman, Lauren Christine
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e17027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17027
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Impact of metabolic syndrome on clinical outcome of castration resistant prostate cancer (CRPC) patients treated with abiraterone and enzalutamide
    Conteduca, V.
    Caffo, O.
    Galli, L.
    Maugeri, A.
    Scarpi, E.
    Maines, F.
    Chiuri, V. E.
    Lolli, C.
    Kinspergher, S.
    Schepisi, G.
    Santoni, M.
    Santini, D.
    Fratino, L.
    Burgio, S. L.
    Salvi, S.
    Menna, C.
    de Giorgi, U.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
    Yang, Ming
    Xie, Wanling
    Mostaghel, Elahe
    Nakabayashi, Mari
    Werner, Lillian
    Sun, Tong
    Pomerantz, Mark
    Freedman, Matthew
    Ross, Robert
    Regan, Meredith
    Sharifi, Nima
    Figg, William Douglas
    Balk, Steven
    Brown, Myles
    Taplin, Mary-Ellen
    Oh, William K.
    Lee, Gwo-Shu Mary
    Kantoff, Philip W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : 2565 - 2573
  • [23] Genetic Polymorphisms in SLCO1B3 and SLCO2B1 May Influence the Racial Difference in the Response to Androgen Deprivation Therapy in Advanced Prostate Cancer
    Fujimoto, N.
    Kubo, T.
    Inatomi, H.
    Hoai, B.
    Yoshida, T.
    Shiota, M.
    Matsumoto, T.
    UROLOGY, 2012, 80 (03) : S80 - S80
  • [24] Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies
    Abdel-Rahman, Omar
    CLINICAL GENITOURINARY CANCER, 2019, 17 (01) : E104 - E112
  • [25] Implications of single nucleotide polymorphisms (SNPs) in androgen related-genes in outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (Abi) and enzalutamide (Enza)
    Aragon, I. M.
    Cendon, Y.
    Lorente, D.
    Lozano Mejorada, R.
    Romero Laorden, N.
    Medina Colmenero, A.
    Puente, J.
    Villatoro, R.
    Vazquez Estevez, S.
    Piulats, J. M.
    Lainez, N.
    Fernandez-Parra, E.
    Gonzalez del Alba, A.
    Hernandez Jorge, A.
    Olmos, B.
    Rivera, L.
    Pacheco, M. I.
    Olmos Hidalgo, D.
    Castro, E.
    ANNALS OF ONCOLOGY, 2019, 30 : 346 - 346
  • [26] Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
    Sissung, TM
    Danesi, R
    Price, DK
    Steinberg, SM
    De Wit, R
    Cox, MC
    Dahut, W
    Figg, W
    Sparreboom, A
    PHARMACOTHERAPY, 2005, 25 (10): : 1479 - 1479
  • [27] The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer
    Belderbos, Bodine P. S.
    De With, Mirjam
    Singh, Rajbir K.
    Agema, Bram C.
    El Bouazzaoui, Samira
    Oomen-de Hoop, Esther
    De Wit, Ronald
    Van Schaik, Ron H. N.
    Mathijssen, Ron H. J.
    Bins, Sander
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (03) : 547 - 553
  • [28] Phase I study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based therapy.
    Singal, R.
    Ramachandran, K.
    Gordian, E.
    Reis, I. M.
    Zhao, W.
    Quintero, C. A.
    Mayo, C.
    Auguste, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer
    Bodine P. S. Belderbos
    Mirjam de With
    Rajbir K. Singh
    Bram C. Agema
    Samira El Bouazzaoui
    Esther Oomen-de Hoop
    Ronald de Wit
    Ron H. N. van Schaik
    Ron H. J. Mathijssen
    Sander Bins
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 547 - 553
  • [30] IMPACT OF POLYMORPHISMS IN ABCB1 AND NRI2 WITH DOCETAXEL RESPONSE FOR CASTRATION-RESISTANT PROSTATE CANCER
    Takata, Ryo
    Nasu, Takashi
    Obara, Wataru
    Mushiroda, Taisei
    Kubo, Michiaki
    Nakagawa, Hidewaki
    Nakamura, Yusuke
    Fujioka, Tomoaki
    JOURNAL OF UROLOGY, 2014, 191 (04): : E508 - E509
12345